Let’s Talk About It: Triple Negative Breast Cancer
Women with Triple Negative Breast Cancer can join Nancy Touhill and peers via video or phone to talk about the topics such as "Cutting-Edge Research on Triple-Negative Breast Cancer (TNBC)" (March 21).
March 21: Cutting-Edge Research on Triple-Negative Breast Cancer (TNBC)
Researchers from the University of Arizona have developed a drug compound that appears to stop cancer cell growth in what's known as triple-negative breast cancer. The drug, which has not yet been tested in humans, has been shown to eliminate tumors in mice, with little to no effect on normal healthy cells, making it potentially nontoxic for patients. The therapy is based on a newly discovered way that a gene known as epidermal growth factor receptor, or EGFR, leads to cancer. EGFR is a long-investigated oncogene—a gene that in certain circumstances can transform a cell into a tumor cell. Join our facilitator Nancy Touhill as she speaks with a researcher to breakdown this information for the TNBC community.
Register to get instructions to join.